C4X Discovery updates on Parkinson's collaboration with e-therapeutics

6 December 2018

UK-based C4X Discovery Holdings (AIM: C4XD) and e-therapeutics (AIM: ETX), a network-driven drug discovery (NDD) company, have updated their collaboration (announced May 1, 2018) to identify novel intervention strategies for the potential treatment of Parkinson’s disease (PD).

This collaboration has identified additional novel biological pathways for the treatment of PD and both companies consider that further work in this area has the potential to transform the treatment landscape for these patients, where there remains a significant unmet need.

The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has already resulted in a number of avenues for novel drug target generation in PD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK